Pyridines

Poxel Announces Presentation of PXL065 Data at the 2019 NASH-TAG Conference

Retrieved on: 
Monday, January 7, 2019
Health, Biotechnology, Clinical trials, Other Health, Research, Other Science, Diabetes, Science, CYP17A1 inhibitors, Pyridines, Thiazolidinediones, Eli Lilly and Company, Pioglitazone, MPC, Chemistry

The presentation titled PXL065, Pioglitazone (pio), and Thiazolidinediones (TZDs): Unravelling Pios superior efficacy for NASH and role of stereoisomers was given on January 5, 2019 in Park City, Utah.

Key Points: 
  • The presentation titled PXL065, Pioglitazone (pio), and Thiazolidinediones (TZDs): Unravelling Pios superior efficacy for NASH and role of stereoisomers was given on January 5, 2019 in Park City, Utah.
  • The presentation also included data showing that PXL065 is a mitochondrial pyruvate carrier (MPC) inhibitor without PPAR activity in a cofactor recruitment assay.
  • In preclinical models, PXL065 exhibited little or no weight gain or fluid retention, side effects mainly associated with the PPAR active, S-pioglitazone.
  • PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 and being developed for the treatment of NASH.

Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis

Retrieved on: 
Tuesday, December 18, 2018
Medicine, Cancer, Cancer treatments, Ribbon symbolism, Health, Protein kinase inhibitors, Breast cancer, Metastatic breast cancer, Pyridines, HER2/neu, Breast cancer management, MammaPrint

Each patient presents with unique patterns of clinical factors with some patients having particularly concerning clinical characteristics that can signal a poor prognosis to oncologists.

Key Points: 
  • Each patient presents with unique patterns of clinical factors with some patients having particularly concerning clinical characteristics that can signal a poor prognosis to oncologists.
  • Lilly is committed to continuing research aimed at helping oncologists optimize care for women with advanced disease.
  • MONARCH 2 is a Phase 3, randomized, double-blind, placebo-controlled trial that enrolled 669 patients with HR+, HER2- metastatic breast cancer who progressed on endocrine therapy.
  • Patients could not have received chemotherapy or more than one line of endocrine therapy for metastatic breast cancer.

Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

Retrieved on: 
Saturday, December 8, 2018
Protein kinase inhibitors, RTT, Cell biology, Chemistry, Cancer, Cyclopentanes, Piperazines, Pyridines, Ribociclib, Metastatic breast cancer, Cyclin-dependent kinase 4, HER2/neu

Kisqali plus endocrine therapy demonstrated consistent efficacy across the MONALEESA trials in patients with and without visceral metastases.

Key Points: 
  • Kisqali plus endocrine therapy demonstrated consistent efficacy across the MONALEESA trials in patients with and without visceral metastases.
  • Kisqali (ribociclib) is the CDK4/6 inhibitor with the largest body of first-line clinical trial evidence demonstrating consistent, superior and sustained efficacy compared to endocrine therapy alone4.
  • Ribociclib + endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: Subgroup analysis of Phase III MONALEESA trials.
  • Management of patients with hormone receptorpositive breast cancer with visceral disease: challenges and treatment options.

Pyridine Market to Reach $783 Mn, Globally, by 2025, at 4.9% CAGR: Says Allied Market Research

Retrieved on: 
Monday, November 19, 2018
Chemistry, Organic chemistry, Pyridines, Functional groups, Picoline, Amine oxide, 3-Methylpyridine, 2-Methylpyridine

Allied Market Research published a report, titled, Pyridine Market by Type (Pyridine N-Oxide, Alpha Picoline, Beta Picoline, Gamma Picoline, and 2-Methyl-5-Ethylpyridine) and Application (Agrochemicals, Pharmaceuticals, Chemicals, Foods, and Others): Global Opportunity Analysis and Industry Forecast, 2018-2025.

Key Points: 
  • Allied Market Research published a report, titled, Pyridine Market by Type (Pyridine N-Oxide, Alpha Picoline, Beta Picoline, Gamma Picoline, and 2-Methyl-5-Ethylpyridine) and Application (Agrochemicals, Pharmaceuticals, Chemicals, Foods, and Others): Global Opportunity Analysis and Industry Forecast, 2018-2025.
  • Increase in demand for pyridine and its derivatives, especially from agrochemicals and pharmaceutical industries due to their multiple chemical functionalities is driving factor of the global pyridine market.
  • Moreover, increased use of pyridine as a denaturant in antifreeze mixtures drives the growth of the market.
  • The pyridine n-oxide segment captured the highest market share of more than one-third in 2017 and would maintain its dominance through 2025.

China Omeprazole Market Report, 2018-2022: Sales, Competition, Manufacturers, Prices & Market Prospects

Retrieved on: 
Friday, November 2, 2018
Proton pump inhibitors, Chemistry, Benzimidazoles, Pyridines, Sulfoxides, AstraZeneca, Organic chemistry, Medicine, Omeprazole, Lansoprazole, Zeneca, Esomeprazole

In 1988, Swedish company Astra (now known as AstraZeneca) developed a new anti-ulcer drug proton pump inhibitor Omeprazole (trade name: Losec).

Key Points: 
  • In 1988, Swedish company Astra (now known as AstraZeneca) developed a new anti-ulcer drug proton pump inhibitor Omeprazole (trade name: Losec).
  • With the launch of generic Omeprazole in China, Chinese pharmaceutical companies keep scrambling for market share from AstraZeneca.
  • Overall, the market size of Omeprazole in China is growing, with the sales value exceeding CNY 1.3 billion in 2017.
  • 2 Sales of Omeprazole in China, 2013-2017
    2.3 Sales of Omeprazole by Dosage Form in China, 2013-2017

Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA

Retrieved on: 
Thursday, November 1, 2018
Cancer, RTT, Carcinoma, Cemiplimab, Basal-cell carcinoma, Chloroarenes, Pyridines, Vismodegib, Skin cancer, Squamous cell skin cancer

TAIPEI, Taiwan and SAN DIEGO, Nov. 1, 2018 /PRNewswire/ -- Senhwa Biosciences Inc. (TPEx: 6492) announced today that FDA has approved its IND application for basal cell carcinoma (BCC).

Key Points: 
  • TAIPEI, Taiwan and SAN DIEGO, Nov. 1, 2018 /PRNewswire/ -- Senhwa Biosciences Inc. (TPEx: 6492) announced today that FDA has approved its IND application for basal cell carcinoma (BCC).
  • A recent example to follow is Sanofi and Regeneron's Libtayo, approved for metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) on Sept. 28, 2018.
  • Basal cell carcinoma (BCC) is the most common type of skin cancer.
  • Most basal cell carcinoma can be surgically removed but for those tumors unresectable are currently treated by two approved targeted drugs (both are SMO inhibitors, Erivedge and Odomzo).

Grünenthal Agrees US$ 922 m Deal With AstraZeneca for Nexium and Vimovo

Retrieved on: 
Tuesday, October 30, 2018
Chemistry, Pharmacology, AstraZeneca, Benzimidazoles, Proton pump inhibitors, Pyridines, Sulfoxides, Esomeprazole, Naproxen/esomeprazole magnesium, Tablet

Grnenthal today announced that it has agreed to acquire AstraZeneca's European rights to Nexium and the global (ex US and Japan) rights to Vimovo for a total consideration of up to US$ 922 m ( 811 m).

Key Points: 
  • Grnenthal today announced that it has agreed to acquire AstraZeneca's European rights to Nexium and the global (ex US and Japan) rights to Vimovo for a total consideration of up to US$ 922 m ( 811 m).
  • Therefore, combining Grnenthal's extensive pain expertise with the well-established products Nexium and Vimovo is a perfect strategic fit."
  • Total prescription Nexium 2017 sales for in-scope markets were US$ 248 m ( 220 m).
  • Nexium is available in several formulations: Nexium gastro-resistant granules for oral suspension, Nexium gastro-resistant Multi-Unit Pellet System (Nexium MUPS) tablets, and Nexium injection/infusion with varying approved indications.

Global CML Market Report - 2022

Retrieved on: 
Thursday, October 18, 2018
Chemistry, Cancer, Organic chemistry, Piperazines, Pyrimidines, Chronic myeloid leukemia, Leukemia, Pyridines, Chronic myelogenous leukemia, Bcr-Abl tyrosine-kinase inhibitor, Philadelphia chromosome, ABL

LONDON, Oct. 18, 2018 /PRNewswire/ -- Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder resulting from the neoplastic transformation of the primitive hematopoietic stem cell.

Key Points: 
  • LONDON, Oct. 18, 2018 /PRNewswire/ -- Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder resulting from the neoplastic transformation of the primitive hematopoietic stem cell.
  • However, it is anticipated to become the most widespread hematologic disorders in the globe by 2022.
  • The main unmet needs in CML are overcoming TKI resistance and addressing patients with accelerated or blast phase disease.
  • At Present, existing BCR-ABL inhibitors form the stronghold of CML treatment comprises first-generation imatinib and more effective second-generation BCR-ABL inhibitors nilotinib and dasatinib, with ponatinib and bosutinib having been lately approved for market inclusion.

Taiho Oncology Presents Real-World Adherence Data for LONSURF® (trifluridine and tipiracil) in Metastatic Colorectal Cancer at ASCO Quality of Care Symposium

Retrieved on: 
Friday, September 28, 2018
Chemistry, Medicine, Health, Chloroarenes, Pyridines, Regorafenib, Ureas, Antineoplastic drugs, Combination drugs, Taiho Pharmaceutical, Trifluridine/tipiracil, Tipiracil

PRINCETON, N.J., Sept. 28, 2018 /PRNewswire/ --Taiho Oncology, Inc. today announced real-world adherence data for patients with metastatic colorectal cancer (mCRC) who were treated with LONSURF(trifluridine and tipiracil) or Stivarga(regorafenib).

Key Points: 
  • PRINCETON, N.J., Sept. 28, 2018 /PRNewswire/ --Taiho Oncology, Inc. today announced real-world adherence data for patients with metastatic colorectal cancer (mCRC) who were treated with LONSURF(trifluridine and tipiracil) or Stivarga(regorafenib).
  • * In this retrospective study, medication adherence was assessed among adult patients with mCRC receiving LONSURF (469) or regorafenib (311).
  • Additionally, patients receiving LONSURF before regorafenib remained on treatment longer than those receiving regorafenib followed by LONSURF.
  • In Japan, Taiho Pharmaceutical has been marketing LONSURF for the treatment of metastatic advanced or recurrent colorectal cancer since 2014.

Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer

Retrieved on: 
Monday, September 24, 2018
Breakthrough therapy, Clinical medicine, Benzamides, Carbamates, Entinostat, Pyridines, Pembrolizumab, Emergent, Medicine, Chemistry

A copy of the presentation is available via the Syndax website at http://www.syndax.com/science/publications/ .

Key Points: 
  • A copy of the presentation is available via the Syndax website at http://www.syndax.com/science/publications/ .
  • Updated data continue to demonstrate a manageable toxicity profile for the entinostat-pembrolizumab combination, with treatment emergent adverse events observed consistent with those previously reported.
  • The Company will release the results of the PFS analysis following its review, and anticipates communicating this in the fourth quarter.
  • Syndax Pharmaceuticalsis a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.